Corton Capital Inc. Makes New $186,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)

Key Points

• Corton Capital Inc. invested approximately $186,000 in Keros Therapeutics by purchasing 18,212 shares during the first quarter.
• Institutional ownership of Keros Therapeutics stands at 71.56%, with several investors increasing their stakes significantly in recent quarters.
• Keros Therapeutics posted earnings of $3.62 per share for the last quarter, exceeding expectations and marking a substantial improvement from the previous year's loss.

Corton Capital Inc. purchased a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,212 shares of the company's stock, valued at approximately $186,000.

A number of other institutional investors have also recently made changes to their positions in KROS. MetLife Investment Management LLC grew its holdings in Keros Therapeutics by 6.0% in the 4th quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock worth $286,000 after acquiring an additional 1,027 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Keros Therapeutics by 7.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,184 shares of the company's stock worth $303,000 after acquiring an additional 1,386 shares during the last quarter. Virtus ETF Advisers LLC grew its holdings in Keros Therapeutics by 107.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. GAMMA Investing LLC grew its holdings in Keros Therapeutics by 7,690.3% in the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock worth $237,000 after acquiring an additional 2,384 shares during the last quarter. Finally, FNY Investment Advisers LLC bought a new stake in Keros Therapeutics in the 1st quarter worth $25,000. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Up 0.6%

Shares of KROS stock opened at $14.46 on Friday. The company has a 50 day moving average price of $14.03 and a 200-day moving average price of $12.64. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $72.37. The firm has a market capitalization of $587.37 million, a PE ratio of -80.33, a P/E/G ratio of 2.62 and a beta of 1.26.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a net margin of 1.96% and a return on equity of 0.75%. The firm had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. During the same period in the previous year, the company earned ($1.21) earnings per share. Analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on KROS. Bank of America lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their price target for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Scotiabank dropped their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. HC Wainwright dropped their target price on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Truist Financial dropped their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research report on Friday, May 30th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Keros Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $30.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.